Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
复制标题
嵌合抗原受体 (CAR) 自然杀伤 (NK) 细胞疗法：利用先天免疫的力量。
DOI：
10.1111/bjh.17186
复制
发表时间：
2021-04
影响因子：
6.5
通讯作者：
Rezvani, Katayoun
中科院分区：
文献类型：
--
作者：
Rafei, Hind;Daher, May;Rezvani, Katayoun
关键词：
嵌合抗原受体(CAR)T细胞是一种迅速崛起的癌症治疗方法，对难治性淋巴系统恶性肿瘤有显著的疗效。然而，它们的广泛临床应用受到与细胞因子释放综合征和神经毒性相关的毒性、其制造的逻辑复杂性、自体CAR-T细胞的成本和治疗时间以及与同种异体CAR-T细胞相关的移植物抗宿主病(GvHD)风险的限制。自然杀伤(NK)细胞因其现成的可获得性和安全性而成为基于汽车的治疗的一种有前途的细胞来源。NK细胞是先天免疫系统的一部分，是抵御病原体和癌细胞的第一道防线。它们产生细胞因子并介导细胞毒性，而不需要事先致敏，并具有与其他免疫细胞相互作用和激活的能力。用于免疫治疗的NK细胞可以来自多种来源，如扩增的自体或异体外周血、脐带血、造血干细胞、诱导的多能干细胞以及细胞系。基因工程NK细胞表达CAR已经显示出令人印象深刻的临床前结果，目前正在进行多项临床试验。在这篇综述中，我们讨论了在CAR NK细胞治疗领域中的临床前和临床试验进展，以及克服所遇到的挑战的策略。
Chimeric antigen receptor (CAR) T cells are a rapidly emerging form of cancer treatment, and have resulted in remarkable responses in refractory lymphoid malignancies. However, their widespread clinical use is limited by toxicity related to cytokine release syndrome and neurotoxicity, the logistic complexity of their manufacturing, cost and time-to-treatment for autologous CAR-T cells, and the risk of graft-versus-host disease (GvHD) associated with allogeneic CAR-T cells. Natural killer (NK) cells have emerged as a promising source of cells for CAR-based therapies due to their ready availability and safety profile. NK cells are part of the innate immune system, providing the first line of defence against pathogens and cancer cells. They produce cytokines and mediate cytotoxicity without the need for prior sensitisation and have the ability to interact with, and activate other immune cells. NK cells for immunotherapy can be generated from multiple sources, such as expanded autologous or allogeneic peripheral blood, umbilical cord blood, haematopoietic stem cells, induced pluripotent stem cells, as well as cell lines. Genetic engineering of NK cells to express a CAR has shown impressive preclinical results and is currently being explored in multiple clinical trials. In the present review, we discuss both the preclinical and clinical trial progress made in the field of CAR NK-cell therapy, and the strategies to overcome the challenges encountered.
登录
查看更多内容
DOI：
10.4049/jimmunol.0804224
发表时间：
2009-05-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Korbel DS;Norman PJ;Newman KC;Horowitz A;Gendzekhadze K;Parham P;Riley EM
通讯作者：
Riley EM
影响因子：
11.2
作者：
Chang, Yu-Hsiang;Connolly, John;Campana, Dario
通讯作者：
Campana, Dario
影响因子：
11.4
作者：
Chen KH;Wada M;Pinz KG;Liu H;Lin KW;Jares A;Firor AE;Shuai X;Salman H;Golightly M;Lan F;Senzel L;Leung EL;Jiang X;Ma Y
通讯作者：
Ma Y
影响因子：
64.5
作者：
André P;Denis C;Soulas C;Bourbon-Caillet C;Lopez J;Arnoux T;Bléry M;Bonnafous C;Gauthier L;Morel A;Rossi B;Remark R;Breso V;Bonnet E;Habif G;Guia S;Lalanne AI;Hoffmann C;Lantz O;Fayette J;Boyer-Chammard A;Zerbib R;Dodion P;Ghadially H;Jure-Kunkel M;Morel Y;Herbst R;Narni-Mancinelli E;Cohen RB;Vivier E
通讯作者：
Vivier E
影响因子：
14.2
作者：
Campbell, Kerry S.;Hasegawa, Jun
通讯作者：
Hasegawa, Jun